SCHEMBL6202033

SCHEMBL6202033

O=Cc1c(Cl)nc(-c2ccccc2)n1Cc1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
GAA P10253 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.45
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
LMNA P02545 5/20 0.43
KDM4E B2RXH2 2/20 0.43
RECQL P46063 1/20 0.43
RAB9A P51151 1/20 0.43
GALR3 O60755 1/20 0.43
NR2F2 P24468 1/20 0.43
PDE6D O43924 1/20 0.43
ALDH2 P05091 1/20 0.43
ALDH3A1 P30838 1/20 0.43
TP53 P04637 1/20 0.42
CYP11B1 P15538 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11160756 0.90 ALDH1A1 (0.51) ALDH1A1GAACYP1A2CYP2D6CYP2C9
SCHEMBL11097622 0.89 ALDH1A1 (0.56) ALDH1A1GAASMN1; SMN2NR1H2NR1H3
SCHEMBL5174047 0.84 VDR (0.41) ALDH1A1GAACYP1A2CYP2D6CYP2C9
SCHEMBL11162148 0.83 LMNA (0.49) ALDH1A1GAACYP1A2CYP2D6CYP2C9
SCHEMBL5174986 0.81 AGTR1 (0.39) ALDH1A1GAACYP1A2CYP2D6CYP2C9
SCHEMBL11098803 0.79 IDO1 (0.43) ALDH1A1GAACYP1A2CYP2D6CYP2C9
SCHEMBL11093772 0.79 ALDH1A1 (0.59) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL11163273 0.79 ALDH1A1 (0.59) ALDH1A1GAASMN1; SMN2LMNAKDM4E
SCHEMBL7609835 0.78 GP6 (0.42) ALDH1A1SMN1; SMN2AGTR2GP6
SCHEMBL11095083 0.78 TP53 (0.55) ALDH1A1GAASMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1185527-B1 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA GMBH (DE) 2005-07-27 EP disclosed
CN-1176911-C Benzidine-sulfuryl radical substitution pentatomic heterocycle, its preparation method, its medicinal and composition �ճ�˹�عɷݹ�˾ 2004-11-24 CN disclosed
US-6486189-B2 TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE HOECHST AKTIENGESELLSCHAFT (DE) 2002-11-26 US disclosed
US-6429222-B2 HYPOTENSIVE AGENT, ENDOTHELIAL DAMAGE, ARTERIOSCLEROSIS, ANTIDIABETIC AGENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-08-06 US disclosed
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-06-20 US disclosed
US-20020045761-A1 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them KLEEMANN HEINZ-WERNER (DE) 2002-04-18 US disclosed
EP-1185527-A1 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2002-03-13 EP disclosed
US-6335451-B1 ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2002-01-01 US disclosed
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2001-08-30 US disclosed
US-6235766-B1 HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-22 US disclosed
WO-2000068226-A1 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-11-16 WO disclosed
EP-0855392-A2 Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1998-07-29 EP disclosed
CN-1188760-A Benzidine-sulfuryl radical substitution pentatomic heterocycle, its preparation method, its medicinal and composition HOECHST AG (DE) 1998-07-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AGTR1, NPR1, EDNRB ALDH1A1 1413/4885GAA 2379/4885CYP1A2 2063/4885
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AGTR1, NPR1, EDNRB ALDH1A1 1684/4885GAA 2157/4885CYP1A2 2108/4885
US-20020045761-A1 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them BAX, BCL2, TNNI3 ALDH1A1 160/4885GAA 2799/4885CYP1A2 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.